FDA to review Acusphere's Imagify

Ultrasound contrast developer Acusphere said that the U.S. Food and Drug Administration (FDA) has accepted its Imagify new drug application (NDA) for review.

Imagify is an ultrasound contrast agent designed to assess myocardial perfusion, according to the Watertown, MA-based firm.

Related Reading

Acusphere revenues flat for Q1 2008, May 9, 2008

Acusphere submits NDA for Imagify, April 29, 2008

Acusphere cuts annual net loss, March 17, 2008

Acusphere gets Nasdaq warning letter, January 14, 2008

Acusphere reports Q3 results, November 9, 2007

Copyright Β© 2008 AuntMinnie.com

Page 1 of 509
Next Page